Vertex Pharmaceuticals ( VRTX) pushed the Health Care sector lower today making it today's featured Health Care loser. The sector as a whole closed the day down 0.9%. By the end of trading, Vertex Pharmaceuticals fell $1.32 (-2%) to $63.38 on average volume. Throughout the day, 3.9 million shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 3.3 million shares. The stock ranged in price between $62.88-$66.10 after having opened the day at $64.37 as compared to the previous trading day's close of $64.70. Other company's within the Health Care sector that declined today were: Tianyin Pharmaceutical ( TPI), down 32.2%, Rosetta Genomics ( ROSG), down 22.9%, Lakeland Industries ( LAKE), down 20.6%, and Dynatronics Corporation ( DYNT), down 16%. Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for the treatment of serious diseases worldwide. Vertex Pharmaceuticals has a market cap of $13.09 billion and is part of the drugs industry. The company has a P/E ratio of 42.8, below the average drugs industry P/E ratio of 45.3 and above the S&P 500 P/E ratio of 17.7. Shares are up 86.8% year to date as of the close of trading on Monday. Currently there are 12 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and five rate it a hold. TheStreet Ratings rates Vertex Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the growth in the company's net income has been quite unimpressive.